Andreas Engert

Andreas Engert's AcademicInfluence.com Rankings

Andreas Engert

Law

#2142

World Rank

#2677

Historical Rank

International Law

#374

World Rank

#479

Historical Rank

law Degrees

Download Badge

Why Is Andreas Engert Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Andreas Engert's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. (2012) (1311)
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. (1998) (931)
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. (2010) (779)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. (2016) (729)
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). (1999) (635)
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. (2006) (579)
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials (2009) (554)
Hodgkin lymphoma. (2020) (522)
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial (2012) (507)
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018) (462)
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. (2009) (439)
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. (2003) (422)
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. (2003) (385)
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. (2010) (374)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. (2007) (363)
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. (2009) (360)
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. (2007) (341)
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. (2003) (308)
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. (2016) (293)
New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. (2002) (280)
Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. (2005) (272)
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. (2012) (263)
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. (2008) (255)
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. (2012) (247)
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. (1998) (246)
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group (2017) (243)
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. (2007) (242)
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions (2012) (228)
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. (2011) (226)
Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function (2008) (225)
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. (2005) (219)
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. (2002) (210)
Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis (2011) (209)
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) (2017) (207)
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. (2015) (203)
Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. (2005) (201)
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. (2013) (199)
Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. (2008) (197)
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. (1998) (196)
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. (2002) (195)
A genome-wide association study of Hodgkin Lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21, and 10p14 (GATA3) (2010) (194)
Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. (2000) (192)
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. (2008) (191)
Compatible-Solute-Supported Periplasmic Expression of Functional Recombinant Proteins under Stress Conditions (2000) (183)
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. (2001) (183)
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. (2007) (175)
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). (2008) (173)
Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. (2013) (173)
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (172)
Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. (2005) (168)
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. (2009) (162)
[German Hodgkin's Lymphoma Study Group]. (2001) (159)
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2011) (158)
No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. (2010) (156)
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma (2011) (153)
Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. (2003) (151)
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. (2010) (151)
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). (2005) (148)
Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases § (2008) (148)
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). (2004) (147)
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. (2006) (147)
Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. (2004) (143)
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). (2013) (142)
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. (2002) (141)
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. (2003) (140)
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. (1997) (138)
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial (2015) (136)
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (134)
Erythropoietin or darbepoetin for patients with cancer. (2012) (129)
Aerobic physical exercise for adult patients with haematological malignancies. (2014) (127)
Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. (2005) (125)
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). (2005) (124)
Depletion of Cellular Cholesterol and Lipid Rafts Increases Shedding of CD301 (2004) (119)
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. (2006) (119)
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant (2013) (115)
Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. (2007) (113)
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. (2014) (113)
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. (2003) (113)
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. (2005) (111)
Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) (1998) (111)
Cancer-related anemia and recombinant human erythropoietin—an updated overview (2006) (110)
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. (2019) (108)
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. (2001) (108)
Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). (2008) (107)
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. (2002) (105)
Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? (2000) (105)
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study (2009) (105)
Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study (2016) (104)
Long‐term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma (2010) (102)
The emerging role of immune checkpoint inhibition in malignant lymphoma (2017) (102)
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. (2011) (100)
Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. (2008) (100)
Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. (1990) (98)
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. (2011) (97)
High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. (2008) (97)
Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients (2013) (96)
Rituximab ( Anti-CD 20 Monoclonal Antibody ) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma : A Multicenter Phase II Study (1998) (95)
Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. (2012) (95)
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. (2003) (95)
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. (2020) (94)
Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review (2010) (94)
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (93)
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. (2012) (92)
Erythropoietin for patients with malignant disease. (2004) (92)
Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. (2017) (92)
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). (1998) (91)
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. (2011) (89)
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. (2013) (89)
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. (2016) (88)
Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. (2001) (88)
Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. (2001) (88)
Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. (2000) (86)
Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. (1990) (86)
High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. (2007) (85)
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. (2012) (85)
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. (2016) (84)
Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies. (1993) (83)
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (82)
Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. (2001) (80)
Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. (2005) (79)
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. (2017) (79)
Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin (2000) (77)
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. (2009) (77)
Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. (2004) (76)
Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. (2012) (76)
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma (2013) (75)
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy (2009) (74)
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma (2015) (73)
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. (2003) (72)
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. (2017) (72)
An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETÁ) is a potent immunotoxin against a Hodgkin-derived cell line (1999) (72)
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. (1996) (70)
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma (2017) (70)
Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. (2003) (70)
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. (2015) (70)
Anti‐CD20 monoclonal antibody (rituximab) in the treatment of pemphigus (2005) (69)
Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab (2002) (69)
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. (2013) (69)
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. (2008) (69)
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma (2010) (68)
Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study (2001) (68)
Treatment of pemphigus vulgaris with anti‐CD20 monoclonal antibody (rituximab) (2003) (68)
Clinical applications of granulocyte colony-stimulating factor: an update and summary (2003) (68)
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. (1998) (67)
Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment (2006) (67)
Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma (2014) (67)
High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. (2013) (66)
Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. (1995) (65)
Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma (2007) (65)
Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin’s Lymphoma (2013) (65)
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. (2017) (64)
State of the art in the treatment of Hodgkin lymphoma (2012) (64)
ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro. (2007) (64)
Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature (2003) (64)
Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. (2005) (63)
Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. (2016) (63)
Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the (2004) (63)
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (2005) (63)
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia (1999) (63)
Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group. (2013) (62)
Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. (1990) (62)
The European Hematology Association Roadmap for European Hematology Research: a consensus document. (2016) (62)
Idarubicin: a brief overview on pharmacology and clinical use. (1997) (61)
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. (2013) (61)
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. (2012) (61)
Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. (2013) (60)
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. (2009) (60)
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (2010) (60)
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. (2021) (59)
Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. (2011) (58)
Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. (2013) (58)
Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab (2009) (58)
Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. (2006) (57)
Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. (1998) (57)
Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (2010) (57)
Impact of granulocyte colony‐stimulating factor (CSF) and granulocyte–macrophage CSF in patients with malignant lymphoma: a systematic review (2003) (57)
Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. (2006) (57)
HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin’s lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG) (2005) (56)
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. (2004) (56)
Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. (2009) (55)
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. (2014) (55)
Immunotoxins constructed with anti‐CD25 monoclonal antibodies and deglycosylated ricin a‐chain have potent anti‐tumour effects against human hodgkin cells in vitro and solid hodgkin tumours in mice (1991) (54)
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. (2004) (53)
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. (2001) (53)
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. (2003) (52)
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. (2002) (52)
Incorporating under European Law: The Societas Europaea as a Vehicle for Legal Arbitrage (2008) (52)
A dominant linear B‐cell epitope of ricin A‐chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti‐CD25 immunotoxin (2004) (51)
Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group. (2000) (51)
A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia (2000) (51)
First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation (2016) (50)
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). (2010) (50)
The bispecific immunoligand ULBP2‐aCEA redirects natural killer cells to tumor cells and reveals potent anti‐tumor activity against colon carcinoma (2013) (50)
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma (2017) (49)
Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. (2013) (49)
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. (1998) (49)
Hodgkin Lymphoma-Derived Extracellular Vesicles Change the Secretome of Fibroblasts Toward a CAF Phenotype (2018) (49)
T-cell Non-Hodgkin's Lymphoma in Adults: Clinicopathological Characteristics, Response to Treatment and Prognostic Factors (2002) (48)
Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma (2013) (48)
Current treatment and immunotherapy of Hodgkin's lymphoma. (2005) (47)
Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. (2010) (47)
High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. (2012) (47)
Fludarabine in chronic lymphocytic leukaemia (2006) (47)
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization (1999) (47)
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. (2013) (47)
[Hodgkin's disease]. (1996) (46)
Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-κB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell–Mediated Cytotoxicity (2009) (46)
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. (2012) (45)
Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. (2004) (45)
Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma (2018) (45)
Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma (2009) (44)
Development of new ricin A‐chain immunotoxins with potent anti‐tumor effects against human hodgkin cells in vitro and disseminated Hodgkin tumors in scid mice using high‐affinity monoclonal antibodies directed against the CD30 antigen (1995) (44)
Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning (2000) (44)
Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). (2011) (44)
Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice. (1992) (43)
Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma (2016) (43)
Alemtuzumab for patients with chronic lymphocytic leukaemia. (2012) (43)
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. (2004) (43)
Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. (2006) (43)
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. (2004) (42)
Imaging of central nervous system lymphomas with iodine‐123 labeled rituximab (2005) (42)
Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (42)
A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. (1999) (41)
Does Charter Competition Foster Entrepreneurship? A Difference‐In‐Difference Approach to European Company Law Reforms (2013) (41)
Protrusion‐guided extracellular vesicles mediate CD30 trans‐signalling in the microenvironment of Hodgkin's lymphoma (2014) (39)
Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. (2012) (38)
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro (2016) (38)
Growth of hodgkin cell lines in severely combined immunodeficient mice (1992) (38)
Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma (2008) (37)
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. (2020) (37)
Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages. (2001) (37)
Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study (2013) (37)
Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (37)
Combination of the Human Anti-CD30 Antibody 5F11 with Cytostatic Drugs Enhances Its Antitumor Activity against Hodgkin and Anaplastic Large Cell Lymphoma Cell Lines (2004) (36)
Ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine‐rich domains 2 and 5 (2004) (36)
Recombinant human erythropoietin in oncology: current status and further developments. (2005) (36)
Carboxypeptidase-G 2 Rescue in Cancer Patients with Delayed Methotrexate Elimination after High-dose Methotrexate Therapy (2002) (36)
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. (2018) (36)
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group. (2020) (36)
Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. (1998) (36)
Hodgkin's lymphoma in the elderly: a different disease in patients over 60. (2007) (35)
Treatment of relapsed CD 20 Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated : results of a phase 2 trial of the German Hodgkin Lymphoma Study Group (2002) (35)
Phase I study of domatinostat (4SC‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies (2019) (34)
Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18 (2018) (34)
Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins (1994) (34)
Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group. (2011) (34)
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. (2018) (34)
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci (2017) (34)
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials (2017) (34)
Beacopp Chemotherapy for Advanced Hodgkin’s Disease: Results of Further Analyses of the HD9- and HD12- Trials of the German Hodgkin Study Group (GHSG). (2004) (33)
Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). (2012) (33)
Induction of In Vitro and In Vivo NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma (2011) (33)
High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis. (2014) (32)
Female fertility after cytotoxic therapy – protection of ovarian function during chemotherapy of malignant and non‐malignant diseases (2005) (32)
Current strategies of antibody-based treatment in Hodgkin's disease. (2002) (32)
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. (2015) (32)
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2017) (32)
Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. (1997) (32)
Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells. (2001) (32)
Histopathological features and their prognostic impact in nodular lymphocyte‐predominant Hodgkin lymphoma – a matched pair analysis from the German Hodgkin Study Group (GHSG) (2014) (31)
Recombinant anti‐CD25 immunotoxin RFT5(SCFV)‐ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice (2000) (31)
Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia (2005) (31)
The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines (2013) (31)
Perioperative Granulocyte Colony-Stimulating Factor Does Not Prevent Severe Infections in Patients Undergoing Esophagectomy for Esophageal Cancer: A Randomized Placebo-Controlled Clinical Trial (2004) (31)
Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group (2013) (30)
New drugs in the treatment of Hodgkin's disease. (1998) (30)
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). (2007) (30)
Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation (2018) (30)
Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. (2019) (30)
The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV‐negative cases of classical Hodgkin's lymphoma (2007) (30)
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. (2017) (29)
Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. (2006) (29)
CNS involvement in Hodgkin's lymphoma. (2007) (29)
Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma (2013) (29)
Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF. (2000) (29)
Cocktails of ricin a‐chain immunotoxins against different antigens on hodgkin and sternberg‐reed cells have superior anti‐tumor effects against H‐RS cells in vitro and solid Hodgkin tumors in mice (1995) (29)
Yoga in addition to standard care for patients with haematological malignancies. (2014) (28)
HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody (2005) (28)
Final Analysis: Phase II Study of Oral Panobinostat In Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Hematopoietic Stem Cell Transplant (2010) (28)
Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. (2002) (27)
Translocation (6;9)(p23;q34) in smoldering leukemia and acute nonlymphocytic leukemia. (1987) (27)
Lymphocyte‐predominant and classical Hodgkin's lymphoma – comparison of outcomes (2005) (27)
Perioperative treatment with Filgrastim stimulates granulocyte function and reduces infectious complications after esophagectomy (2000) (26)
Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant (2014) (26)
Balancing risk and benefit in early-stage classical Hodgkin lymphoma. (2018) (26)
Effects of the Anti-VEGF Monoclonal Antibody Bevacizumab in a Preclinical Model and in Patients With Refractory and Multiple Relapsed Hodgkin Lymphoma (2009) (26)
New strategies for the treatment of advanced-stage Hodgkin's lymphoma. (2007) (26)
The emerging role of immunotoxins in leukemia and lymphoma. (1997) (25)
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9 (2018) (25)
BAY 43‐9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines (2011) (25)
Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group. (2009) (25)
Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials. (2017) (25)
TNF-α-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species (2010) (25)
Efficacy of Panobinostat in Phase II Study in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose Chemotherapy with Autologous Stem Cell Transplant. (2009) (25)
Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines. (2004) (25)
Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. (2015) (25)
Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease (2005) (25)
Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation. (1994) (25)
Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG). (2005) (24)
The past: what we have learned in the last decade. (2010) (24)
Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice. (1994) (24)
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia (2008) (24)
ABVD versus BEACOPP for Hodgkin's lymphoma. (2011) (24)
Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma (2006) (24)
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma (2011) (24)
Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF. (1994) (24)
An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines. (2001) (24)
High-Dose Chemotherapy with Autologous Stem Cell Support Is Not Superior to Conventional-Dose Chemotherapy in the First-Line Treatment of Aggressive Non-Hodgkin Lymphoma - Results of a Comprehensive Meta-Analysis. (2004) (24)
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. (2018) (23)
Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial (2010) (23)
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia (2002) (23)
Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group (2016) (23)
Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group. (2008) (23)
Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial. (2009) (23)
Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma. (2019) (23)
Recombinant immunotoxins for the treatment of Hodgkin's disease (Review). (2000) (23)
Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial (2010) (23)
Hodgkin Lymphoma in Adults. (2018) (22)
Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition (2018) (22)
Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome display. (2007) (22)
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma. (2015) (22)
CT and MR imaging in Hodgkin's disease – present and future (2005) (22)
Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. (2004) (22)
Interleukin 10 inhibits cytokine production of human AML cells. (1996) (22)
Inhibition of metalloproteinases enhances the internalization of anti‐CD30 antibody Ki‐3 and the cytotoxic activity of Ki‐3 immunotoxin (2002) (22)
Recent Interim Analysis of the HD11 Trial of the GHSG: Intensification of Chemotherapy and Reduction of Radiation Dose in Early Unfavorable Stage Hodgkin’s Lymphoma. (2005) (22)
Current treatment strategies of the German Hodgkin Study Group (GHSG) (2005) (22)
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). (2007) (21)
The role of additional radiotherapy for primary central nervous system lymphoma. (2014) (21)
Metalloproteinase inhibition augments antitumor efficacy of the anti‐CD30 immunotoxin Ki‐3(scFv)‐ETA′ against human lymphomas in vivo (2004) (21)
Treatment of early-stage Hodgkin lymphoma. (2016) (21)
Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches. (1999) (21)
Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. (2004) (21)
The HD12 Panel of the German Hodgkin Lymphoma Study Group (GHSG): A Quality Assurance Program Based on a Multidisciplinary Panel Reviewing All Patients’ Imaging (2004) (21)
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma. (1997) (20)
Combined Modality Treatment of Hodgkin’s Lymphoma (2009) (20)
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. (2017) (20)
The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. (1998) (20)
Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins. (1991) (20)
Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin’s lymphoma: Results of the fourth interim analysis of the HD 11 trial of the GHSG (2005) (20)
Current developments in the treatment of early-stage classical Hodgkin lymphoma (2016) (20)
Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma (2020) (20)
Intensification of the CHOEP Regimen for High-Grade Non- Hodgkin’s Lymphoma by G-CSF: Feasibility of a 14-Day Regimen (1994) (20)
The Monoclonal Antibodies Campath-1H and Rituximab in theTherapy of Chronic Lymphocytic Leukemia (2000) (19)
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma (2019) (19)
Immunotoxins: is there a clinical value? (1994) (19)
Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial. (2009) (19)
Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up. (2013) (19)
Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. (2019) (19)
Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma. (2004) (19)
How I treat nodular lymphocyte-predominant Hodgkin Lymphoma. (2020) (19)
Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment (2018) (19)
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study. (2016) (19)
Granulocyte Transfusion Therapy for Treatment of Infections after Cytotoxic Chemotherapy (2003) (18)
Soluble Tissue Factor Induces Coagulation on Tumor Endothelial Cells In Vivo if Coadministered With Low-Dose Lipopolysaccharides (2003) (18)
FDG-PET in Hodgkin lymphoma (2008) (18)
NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL (2017) (18)
Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma (2014) (18)
Population Pharmacokinetics of the BEACOPP Polychemotherapy Regimen in Hodgkin’s Lymphoma and its Effect on Myelotoxicity (2007) (18)
Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10 (2005) (18)
The genetics of Hodgkin lymphoma: an overview and clinical implications (2017) (18)
Checkpoint Inhibition in Hodgkin Lymphoma - a Review (2017) (18)
Current and future immunotherapeutic approaches in Hodgkin lymphoma (2016) (17)
CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma. (1999) (17)
Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo. (2007) (17)
PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis. (2016) (17)
Photodynamic therapy mediated induction of accelerated re-endothelialisation following injury to the arterial wall: implications for the prevention of postinterventional restenosis. (2002) (17)
Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude (2017) (17)
Survivors’ perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group (2018) (17)
ABVD or BEACOPP for Advanced Hodgkin Lymphoma. (2016) (17)
Selective killing of B‐cell hybridomas targeting proteinase 3, Wegener's autoantigen (2004) (17)
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis (2011) (17)
A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells (2012) (17)
Recombinant Human Erythropoietin as an Alternative to Blood Transfusion in Cancer-Related Anaemia (2000) (16)
Whole genome sequencing reveals DICER1 as a candidate predisposing gene in familial Hodgkin lymphoma (2018) (16)
Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. (2018) (16)
[Effect of intraoperative blood loss on the function of natural killer cells in tumors of the upper gastrointestinal tract]. (1996) (16)
PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group (2018) (16)
Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG. (1999) (16)
Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study. (2016) (16)
Development of immunotoxins for potential clinical use in Hodgkin's disease. (1996) (16)
Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model. (1994) (16)
The Role of Autologous Transplantation in Hodgkin Lymphoma (2011) (16)
Advances in the treatment of Hodgkin lymphoma (2012) (16)
Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy. (2015) (16)
Addition of Rituximab to BEACOPPescalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study. (2014) (16)
Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. (2011) (16)
How Does the Market React to the Societas Europaea? (2010) (16)
Does Combined Immunochemotherapy with the Monoclonal Antibody Rituximab Improve Overall Survival in the Treatment of Patients with Indolent Non-Hodgkin Lymphoma? Preliminary Results of a Comprehensive Meta-Analysis. (2005) (15)
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi‐agent chemotherapy (2018) (15)
Refractory Hodgkin Lymphoma (2013) (15)
Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG. (2004) (15)
Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma. (2013) (15)
Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma (2005) (15)
Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins. (1994) (15)
Regulating the Closed Corporation (2013) (15)
Hodgkin lymphoma in elderly patients (2018) (14)
A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells. (2003) (14)
Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis (2008) (14)
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. (2020) (14)
Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes. (2016) (14)
Ribosome display and selection of human anti-CD22 scFvs derived from an acute lymphocytic leukemia patient (2008) (14)
Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation. (2008) (14)
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2) (2002) (14)
Checkpoint inhibitors and radiation treatment in Hodgkin’s lymphoma (2016) (14)
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma. (1999) (14)
Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592) (2010) (14)
Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia. (2008) (14)
Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials. (2015) (14)
Ki-4(scFv)–ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice (2000) (14)
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. (1993) (14)
Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation. (2012) (13)
B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG) (2018) (13)
First-line treatment of Hodgkin’s lymphoma (2006) (13)
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. (1998) (13)
Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study (2018) (13)
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant (2014) (13)
German Hodgkin Study Group Phase I Trial Of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) For Older Hodgkin Lymphoma Patients (2013) (13)
A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia. (2005) (13)
A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines. (1996) (13)
Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study (2018) (13)
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. (2011) (13)
Where Do Firms Issue Debt? An Empirical Analysis of Issuer Location and Regulatory Competition in Europe (2010) (13)
Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT). (2010) (13)
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis. (2017) (13)
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy—results of a randomized trial (2003) (13)
Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth. (1996) (12)
Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (2009) (12)
Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitro (2013) (12)
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. (2021) (12)
Current clinical trials in Hodgkin's disease. (1996) (12)
Five-Year Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma. (2015) (12)
Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations (2011) (12)
Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial (2020) (12)
Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients (2021) (12)
High-dose chemotherapy followed by autologous stem cell transplantation for refractory/relapsed Hodgkin lymphoma patients (2011) (12)
Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. (1994) (12)
Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group (2019) (12)
Immunotherapy of Hodgkin's lymphoma (2005) (12)
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). (2018) (12)
Adolescents with Hodgkin lymphoma: old children or young adults? (2012) (11)
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY (2021) (11)
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration (2015) (11)
The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains. (1995) (11)
Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant (2012) (11)
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma. (2007) (11)
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection. (2021) (11)
Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone (2012) (11)
Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT). (2011) (11)
Combining phage display and screening of cDNA expression libraries: a new approach for identifying the target antigen of an scFv preselected by phage display. (2000) (11)
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group (2016) (11)
Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group (2008) (11)
Potent anti‐tumor effects of an anti‐CD24 ricin A‐chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice (1996) (11)
The Challenging Aspects of Managing Adolescents and Young Adults with Hodgkin's Lymphoma (2014) (11)
Life Without Legal Capital: Lessons from American Law (2006) (11)
EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma. (2006) (11)
Lenalidomide In Patients with Relapsed or Refractory Hodgkin Lymphoma. (2010) (11)
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. (2021) (10)
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies (2013) (10)
CD30-positive malignant lymphomas: time for a change of management? (2013) (10)
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase‐I trial (2018) (10)
Intensification of Chemotherapy and Concomitant Reduction of Radiotherapy Dose in Intermediate Stage Hodgkin′s Lymphoma: Results of the Fourth Interim Analysis of the HD 11 Trial of the GHSG. (2004) (10)
Heritability estimates on Hodgkin’s lymphoma: a genomic- versus population-based approach (2014) (10)
FDG-PET for Assessment of Residual Tissue after Completion of Chemotherapy in Hodgkin Lymphoma - Report on the 2nd Interim Analysis of the PET Investigation in the Trial HD15 of the GHSG. (2007) (10)
VII. Management of nodular lymphocyte‐predominant Hodgkin lymphoma (2013) (10)
Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG) (2018) (10)
Hodgkin Lymphoma: A Comprehensive Overview (2020) (10)
Analysis of the tumor microenvironment by whole-slide image analysis identifies low B cell content as a predictor of adverse outcome in advanced-stage classical Hodgkin lymphoma treated with BEACOPP. (2020) (10)
Hodgkin lymphoma: Introduction. (2016) (10)
The evolving role of targeted drugs in the treatment of Hodgkin lymphoma (2017) (10)
The human anti-CD 30 antibody 5 F 11 shows in vitro and in vivo activity against malignant lymphoma ( Short title : Fully human anti-CD 30 antibody ) (2003) (9)
Transnational Hedge Fund Regulation (2010) (9)
The role of PET in Hodgkin’s lymphoma and its impact on radiation oncology (2010) (9)
Ten-year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9) (2007) (9)
Combined Immunochemotherapy with Rituximab Improves Overall Survival in Patients with Follicular and Mantle Cell Lymphoma: Updated Meta-Analysis Results. (2006) (9)
Large mediastinal tumor mass as a prognostic factor in Hodgkin’s lymphoma (2012) (9)
Meta-Analyses of Early-Stage Hodgkin Lymphoma (2010) (9)
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group (2021) (9)
Where Do Firms Issue Debt? An Empirical Analysis of Issuer Location and Regulatory Competition in the European Corporate Debt Market (2015) (9)
Antibodies and antibody‐drug conjugates in the treatment of Hodgkin lymphoma (2014) (9)
Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma (2020) (9)
Controversies in the Treatment of Classical Hodgkin Lymphoma (2018) (9)
Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma (2012) (9)
Experimental therapy in Hodgkin's disease. (1992) (9)
Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL) (2019) (9)
Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) (2015) (9)
Costs of haematological disease high and rising. (2016) (9)
First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study). (2014) (8)
FluCam—a New, 4-Weekly Combination of Fludarabine and Alemtuzumab for Patients with Relapsed Chronic Lymphocytic Leukemia. (2004) (8)
New concepts for relapsed Hodgkin's disease. (2002) (8)
Current clinical trials for the treatment of adult Hodgkin's disease: common strategies and perspectives. (1998) (8)
Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies (2008) (8)
Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation (2017) (8)
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma (2021) (8)
The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant (2012) (8)
Use of G-CSF for granulocyte transfusion therapy. (2000) (8)
Phase II Study of Rituximab in Combination With Fludarabine in Patients With Chronic Lymphocytic Leukemia (2002) (8)
Why Agents Need Discretion: The Business Judgment Rule as Optimal Standard of Care (2014) (8)
The effect of specialized cancer treatment centers on treatment efficacy in Hodgkin's lymphoma. (2012) (8)
Yttrium-90 Ibritumomab Tiuxetan-Induced Complete Remission in a Patient with Classical Lymphocyte-Rich Hodgkin’s Lymphoma (2008) (8)
Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia (2010) (8)
Feasibility and Efficacy of ABVD In Elderly Hodgkin Lymphoma Patients: Analysis of Two Randomized Prospective Multicenter Trials of the German Hodgkin Study Group (HD10 and HD11) (2010) (8)
Granulopoiesis-stimulating factors in the prevention for adverse effects in the therapeutic treatment of malignant lymphoma. (2002) (8)
Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL) (2015) (8)
Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. (2017) (8)
Hodgkin's Lymphoma and Paraneoplastic Phenomena in the Central Nervous System: A Case Report and Review of the Literature (2011) (8)
Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic (2020) (8)
Primary lymphoma of the conjunctiva – a rare manifestation of indolent non-Hodgkin's lymphoma (2001) (7)
First Line Treatment of Advanced Stage Hodgkin Lymphoma with Six Cycles of BEACOPPescalated Results in Superior Overall Survival Compared to ABVD: Results of a Network Meta-Analysis Including 10,011 Patients (2012) (7)
Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group (2008) (7)
Expanded use of rituximab in the management of non-Hodgkin lymphoma (2009) (7)
HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany. (2006) (7)
Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. (2005) (7)
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL (2014) (7)
Hodgkin’s lymphoma: current treatment strategies and novel approaches (2008) (7)
Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma (2010) (7)
Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG) (2016) (7)
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). (2021) (7)
Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma. (2004) (7)
Dose escalated CHOP + etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL (2005) (7)
Pegfilgrastim Supports Delivery of BEACOPP Chemotherapy Administered Every 14 Days. (2004) (7)
Hodgkin’s lymphoma in nuclear medicine: diagnostic and therapeutic aspects (2003) (6)
Application of G-CSF in the Nonneutropenic Host (1998) (6)
Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade) (2016) (6)
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP (2021) (6)
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group (2015) (6)
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial (2021) (6)
Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results (2011) (6)
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP (2020) (6)
Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF. (2000) (6)
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. (2018) (6)
Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial (2014) (6)
EBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM‐PET‐POSITIVE ADVANCED‐STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL (2017) (6)
A consumer network for haematological malignancies (2005) (6)
The in vitro anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice (2002) (6)
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma. (2000) (6)
A New BACOPP Schedule Is Feasible and Effective in Elderly Hodgkin’s Lymphoma Patients - Interim Results of a Multicenter Phase-II Trial of the German Hodgkin Study Group (GHSG). (2005) (6)
Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma. (2006) (6)
Comprar Hodgkin Lymphoma. A Comprehensive Update On Diagnostics And Clinics (Hematologic Malignancies) | Andreas Engert | 9783642127793 | Springer (2010) (6)
First-line treatment of Hodgkin's lymphoma. (2005) (6)
Treatment of elderly Hodgkin lymphoma patients (2019) (6)
“Large Mediastinal Tumor Mass” is a Prognostic Factor in Hodgkin Lymphoma (HL): Is the Definition on the Basis of a Chest Radiograph in the Era of CT Obsolete? (2011) (6)
Nodular lymphocyte-predominant Hodgkin lymphoma (2008) (6)
Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma (2008) (6)
Treatment of lymphocyte-predominant Hodgkin lymphoma. (2008) (6)
Biomarkers and prognosis in malignant lymphomas. (2009) (6)
Dexamethasone, Carmustine, Etoposide, Cytarabine, and Melphalan (Dexa-BEAM) Followed by High-Dose Chemotherapy and Stem Cell Rescue - A Highly Effective Regimen for Patients with Refractory or Relapsed Indolent Lymphoma (2000) (6)
Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center (2019) (6)
Secondary MDS/AML In Hodgkin Lymphoma Patients Treated within German Hodgkin Study Group (GHSG) Clinical Trials After Introduction of the BEACOPP Protocol (2010) (6)
Evidence of Inbreeding in Hodgkin Lymphoma (2016) (6)
Quality control of involved-field radiotherapy for patients with early stage Hodgkin’s lymphoma based on a central prospective review (2012) (6)
The German evidence-based guidelines for Hodgkin’s lymphoma (2013) (6)
Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial) (2021) (6)
Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term fol (2005) (6)
Fludarabine in Combination with Mitoxantrone and Dexamethasone in Relapsed and Refractory Low-Grade Non-Hodgkin’s Lymphoma (1996) (5)
Activity of cetuximab as single agent in a patient with relapsed multiple myeloma (2010) (5)
Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. (2019) (5)
Hodgkin's lymphoma: who needs consolidation treatment? (2015) (5)
Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG) (2014) (5)
Epoetin and Darbepoetin To Treat Cancer Patients: Updated Meta-Analysis Results. (2005) (5)
HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) (2021) (5)
Impact Of Dose Reduction Of Bleomycin and Vincristine In Patients With Advanced Hodgkin Lymphoma Treated With Beacopp: A Comprehensive Analysis Of The German Hodgkin Study Group (GHSG) HD12 and HD15 Trials (2013) (5)
OP31 10-year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma (2007) (5)
Thirteenth biannual report of the Cochrane Haematological Malignancies Group--focus on multiple myeloma. (2006) (5)
Results of a phase II trial of a fludarabine with concomitant application of alemtuzumab in a four-weekly schedule (FluCam) in patients with relapsed CLL. 2nd Interim analysis. (2004) (5)
[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma]. (2006) (5)
Therapy of Hodgkin’s Disease (1993) (5)
9 Future treatment strategies: fact or fiction? (1996) (5)
Quality control of involved field radiotherapy in the HD 13 and HD 14 trials (2016) (5)
The Societas Europaea: Good News for European Firms (2009) (5)
Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma (2016) (5)
Eff ect of initial treatment strategy on survival of patients with advanced-stage Hodgkin ’ s lymphoma : a systematic review and network meta-analysis (2013) (5)
The GHSG Approach to Treating Hodgkin’s Lymphoma (2015) (5)
Secondary Amenorrhoea after Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives during Therapy: A Report from the German Hodgkin Lymphoma Study Group (GHSG). (2004) (5)
Fourth biannual report of the Cochrane Haematological Malignancies Group. (2005) (5)
The role of ifosfamide in the treatment of relapsed and refractory lymphoma. (2001) (5)
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial (2022) (5)
Issues in the treatment of Hodgkin's disease (1998) (5)
Bortezomib Is Not Active in Patients with Relapsed Hodgkin’s Lymphoma: Results of a Prematurely Closed Phase II Study. (2006) (5)
Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. (2008) (5)
Can Network Effects Impede Optimal Contracting in Debt Securities (2013) (5)
Balancing the Risk-Benefit Ratio in the Treatment of Patients With Advanced-Stage Hodgkin Lymphoma. (2016) (5)
New quality assurance program integrating “modern radiotherapy” within the German Hodgkin Study Group (2017) (5)
A Prospectively Randomized Placebo-Controlled Trial of Epoetin-α in Patients with Advanced-Stage Hodgkin Lymphoma: Final Analysis of the GHSG HD15-EPO Trial (2008) (5)
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis (2021) (4)
Treatment of patients with malignant lymphomas with monoclonal antibodies (2000) (4)
[New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology]. (2003) (4)
Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study (2017) (4)
Combined modality treatment for early-stage Hodgkin’s lymphoma: the GHSG experience (2009) (4)
Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group. (2019) (4)
Allied by Surprise? The Economic Case For an Anti-Discrimination Statute (2003) (4)
An overview of the Third International Symposium on Hodgkin's Lymphoma (1996) (4)
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered (2018) (4)
Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial (2019) (4)
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival (2010) (4)
A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma (2013) (4)
Hodgkin's disease. Future treatment strategies: fact or fiction? (1996) (4)
Intraventricular application of rituximab as a treatment option in patients with CNS lymphoma and leptomeningeal disease. (2004) (4)
CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN (2016) (4)
Fourth interim analysis of the HD R2 study, a europeanmulticenter trial for patients with relapsed Hodgkin lymphoma (2007) (4)
The value of prospective radiotherapy treatment planning in the multicentric German Hodgkin lymphoma study group (2001) (4)
A Phase 1 Study Of JNJ-40346527, a Colony Stimulating Factor-1 Receptor (CSF-1R) Inhibitor, In Patients With Relapsed Or Refractory Hodgkin Lymphoma (2013) (4)
CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation (2012) (4)
Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) Randomized HD11 Trial (2010) (4)
Networks and Lemons in the Market for Contract Law (2012) (4)
Multi-centre, phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: Promising preliminary results (2004) (4)
2-weekly vs 3-weekly CHOP with and without Etoposide in Young Patients with Low-Risk Aggressive Non-Hodgkins Lymphoma Results of the Completed NHL-B-1 Trial of the DSHNHL (2002) (4)
Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma (2015) (4)
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma. (2010) (4)
A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. (2003) (4)
Exhaustive circulating tumor DNA sequencing reveals the genomic landscape of Hodgkin lymphoma and facilitates ultrasensitive detection of minimal residual disease (2021) (4)
Relapsed Hodgkin Lymphoma in Elderly Patients: A Comprehensive Analysis From the German Hodgkin Study Group (GHSG) (2011) (4)
Intracranial transplantation of human hematopoietic cell lines in nude mice: a preclinical screening model for cytostatic drugs. (1987) (4)
Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer) (2017) (4)
Fourteenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Autologous Stem Cell Transplantation in Hematological Malignancies. (2012) (3)
PET positivity – the agony of choice: response assessment and interpretation of increased FDG uptake of residual mediastinal tissue after frontline therapy in Hodgkin lymphoma (2020) (3)
Thrombosis in Hodgkin Lymphoma Patients: Incidence, Time Points, Risk Factors and Impact of Stage and Treatment (2016) (3)
Eight Cycles of Escalated-Dose BEACOPP Compared With FourCycles of Escalated-Dose BEACOPP Followed by Four Cycles ofBaseline-Dose BEACOPP With or Without Radiotherapy in PatientsWith Advanced-Stage Hodgkin’s (2011) (3)
Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial (2019) (3)
Fifth biannual report of the Cochrane Haematologic Malignancies Group--Focus on multiple myeloma. (2006) (3)
XVII. Treatment of advanced‐stage Hodgkin lymphoma (2015) (3)
Non‐Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group (2021) (3)
Fertility and Gonadal Function After Treatment of Early Unfavorable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) (2011) (3)
Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group (2021) (3)
Infradiaphragmatic Hodgkin Lymphoma In Patients Treated With State-Of-The-Art Therapies: A Risk Factor Analysis From The German Hodgkin Study Group (GHSG) HD13 and HD14 Trials (2013) (3)
Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial (2020) (3)
Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG) (2012) (3)
Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma? (2009) (3)
930 A clinical phase I study of an anti-CD25-deglycosylated ricin A-chain immunotoxin (RFT5-SMPT-DGA) in patients with refractory Hodgkin's disease (1995) (3)
The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab. (2005) (3)
Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group (2016) (3)
One size for all in Hodgkin lymphoma? (2011) (3)
Different Outcome for Angioimmunoblastic T-Cell Lymphoma (AIL) and Peripheral T-Cell Lymphoma Unspecified (PTCL-U) Following Upfront Autologous Stem Cell Transplantation. (2006) (3)
Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte‐predominant Hodgkin lymphoma (2022) (3)
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial (2022) (3)
Concomitant treatment of patients with relapsed/refractory CLL using a combination of fludarabine and alemtuzumab is highly effective: Final results of a phase-II study (2005) (3)
A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results, (2011) (3)
Response-adapted Therapy using FDG-PET after BEACOPP-chemotherapy in Advanced Stage Hodgkin's Lymphoma - An Interim Analysis of the German Hodgkin Study Group (GHSG) Trial HD15 (2008) (3)
Tumor Cell-Derived HLA-B-Associated Transkript 3 (BAT3) Is a Ligand for NKp30 and Activates NK Cells. (2006) (3)
Shareholder Activism in Germany (2019) (3)
The HD 12 panel of the German Hodgkin lymphoma study group (GHSG) - a quality assurance program based on a multidisciplinary panel reviewing all patients’ imaging (2001) (3)
AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial (2020) (3)
Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL Study Group (2008) (3)
Therapy-Related Myeloid Neoplasms in Patients Treated for Hodgkin Lymphoma (2011) (3)
Treatment of advanced-stage hodgkin lymphoma: let us face the facts. (2013) (3)
Preventing Infections in Cancer Patients: Antibiotics, Hematopoetic Growth Factors or Both? a Network Analysis (2008) (3)
Yoga for haematological malignancies (2012) (3)
The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG) (2008) (3)
PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 by the GHSG (2019) (3)
Chemotherapy: Hodgkin lymphoma—absence of evidence not evidence of absence! (2011) (3)
Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment (2018) (3)
Doxorubicin, Vinblastine and Dacarbazine with or without Bleomycin for Older Patients with Early Stage Favorable Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials (2014) (2)
Updated phase I data of AFM13: A bispecific tandem antibody (TandAb) in relapsed/refractory (R/R) Hodgkin lymphoma (HL). (2014) (2)
R-CHOP in NLPHL: who should receive it? (2017) (2)
Open Access is the Plan S Way Forward in Hematology Research (2020) (2)
Repetitive High-Dose Therapy with Dose Escalated CHOP + Etoposide Followed by Autologous Stem Cell Transplantation (Mega-CHOEP) in Younger Patients with Primary Diagnosis of Aggressive NHL and Elevated LDH at Diagnosis: Final Analysis. (2004) (2)
Alemtuzumab for chronic lymphocytic leukaemia (2009) (2)
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial (2022) (2)
Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia. (2008) (2)
Experimental chemotherapy of heterotransplanted Hodgkin- and non-Hodgkin-lymphoma cell lines in nude mice. (1984) (2)
6th International Consensus Conference on the Treatment of Primary Breast Cancer (1998) (2)
Involved-Field Radiotherapy prevents recurrences in the early stages of Hodgkin's lymphoma in PET-negative patients after ABVD Chemotherapy Relapse Analysis of GHSG Phase III HD16 Trial. (2021) (2)
Escalated BEACOPP Versus ABVD-Like Chemotherapy for Hodgkin Lymphoma Patients: a Cochrane Review. (2009) (2)
[Limits and value of chemotherapy in elderly patients]. (1994) (2)
[Anti-angiogenesis: a new approach to tumor therapy?]. (1999) (2)
2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD—Interim Ahan Radiotherapy Alone in Early Stage HD—Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany (1999) (2)
Rituximab in Relapsed Lymphocyte Predominant Hodgkin’s Disease (LPHD). Long-Term Results of a Phase-II Study from the German Hodgkin Lymphoma Study Group (GHSG). (2005) (2)
Nodular lymphocyte-predominant Hodgkin’s lymphoma (2006) (2)
Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche. (2020) (2)
Interim PET for prognosis in adults with Hodgkin lymphoma: a prognostic factor exemplar review (2017) (2)
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma (2022) (2)
Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies. (2012) (2)
Implementation and Evaluation of a Central Coordination Office for Clinical Trials in a Tertiary Care Hospital (2005) (2)
Relapse Analysis After Radiation Therapy of PET-Positive Residual Tumors of Patients With Advanced Stage Hodgkin Lymphoma Treated in the HD15 Trial of the German Hodgkin Study Group (GHSG) (2013) (2)
A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma. (1997) (2)
Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i) (2018) (2)
Final results of the HDR2 study – A european multicenter trial in patients with relapsed Hodgkin lymphoma. (2009) (2)
Outcomes of anti‐programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real‐world analysis (2022) (2)
Antibiotics plus granulocyte colony-stimulating factor reduces febrile neutropenia in the first cycle of chemotherapy in people with small-cell lung cancer. (2006) (2)
The First Year of HemaSphere and Many More to Come. (2018) (2)
[Non-Hodgkin lymphoma and pregnancy]. (1990) (2)
Longitudinal Evaluation of Quality of Life and Fatigue In Hodgkin Lymphoma Patients (2010) (2)
Market Standards in Financial Contracting: The Euro’s Effect on Debt Securities (2018) (2)
An anti-GD 2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines (2)
Affordability of Medicines a Top Priority for EHA: Toward a Fair Pricing Model for Innovative Medicines (2017) (2)
An overview of the Second International Symposium on Hodgkin's disease. (1992) (2)
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma. (2014) (2)
Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factors. (2009) (2)
Reply to H.J.A. Adams et al, E.A. Hawkes et al, and C.F. Hess et al. (2017) (2)
Monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia (2009) (2)
Suicide in European Hodgkin Lymphoma Patients (2016) (2)
Assessment of residual bulky tumor using FDG-PET in patients with advanced stages after completion of chemotherapy. Final report of the GHSG HD15 trial (2012) (2)
Involved-field (IF) Versus Extended-field (EF) Radiation Therapy (RT) for Patients in Early Unfavorable Stages of Hodgkin Lymphoma: 10-year Update of the HD8 Trial of the German Hodgkin Study Group (GHSG) (2012) (2)
Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myelogenous Leukemia: To Transplant or Not to Transplant? A Systematic Review of International Guidelines. (2009) (2)
Epoetins and mortality in patients with cancer – Authors' reply (2009) (2)
Introducing the HemaSphere Controversies Series (2019) (2)
Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. (2012) (2)
Multi-centre, phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: Promising preliminary results. (2004) (2)
Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma. (2007) (2)
Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and IF-RT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial (2008) (2)
Mortality during Treatment of Patients with Advanced Hodgkin’s Lymphoma Undergoing Dose Escalated BEACOPP Chemotherapy: An Analysis of the German Hodgkin Study Group (GHSG). (2005) (2)
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. (2022) (2)
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial (2019) (2)
Predictive Value of Positron Emission Tomography/Computed Tomography After ABVD-Based Chemotherapy in Early-Stage Hodgkin Lymphoma. (2019) (2)
Chronic fatigue syndrome (1990) (2)
An overview of the Fourth International Symposium on Hodgkin's Disease. Recent advances in basic and clinical research. (1998) (2)
Fatigue in Hodgkin Lymphoma Patients: Longitudinal Evaluation and Curve Types up to 5 Years (2014) (2)
Non-Hodgkin’s Lymphoma (1997) (2)
Preliminary Phase II Study Results of BBR2778 in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma. (2004) (2)
Tipifarnib Is Cytotoxic and a Drug Transporter Inhibiting Chemosensitizer in Hodgkin Lymphoma Tumor Cells. (2007) (2)
Hodgkin's lymphoma: new insights in an old disease. Preface. (2007) (1)
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors. (2011) (1)
Corticosteroids for preventing graft‐versus‐host disease (2004) (1)
Allogeneic Stem Cell Transplantation for Hodgkin's Disease From Sibling and Unrelated Donors: The German Cooperative Transplantation Study Group Experience. (2009) (1)
NK Cells in Hodgkin Lymphoma Are Impaired but Can Be Activated (2011) (1)
Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG). (2012) (1)
Market Standards in Public Sector Debt Contracting (2013) (1)
Trends and socio-economic inequalities in cancer survival of patients with Hodgkin's lymphoma diagnosed in England and Wales between 1986 and 1999 (2005) (1)
[Chronic lymphatic leukemia. Progress in diagnosis and therapy]. (1996) (1)
Monoclonal Antibody Therapy of Patients with Non-Hodgkin´s Lymphomas (1999) (1)
Discrimination of an Early Unfavorable Risk Group Has Significant Impact On Treatment Outcome in Early-Stage Hodgkin Lymphoma: An Analysis of International Staging Definitions and Risk Factors (2012) (1)
Clinical Outcomes of Patients with 3rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group (2017) (1)
The Chemokine CCL17/TARC as a Biomarker in Hodgkin Lymphoma (2013) (1)
Volumetric assessment of mediastinal lymphoma masses in Hodgkin lymphoma (2019) (1)
P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial (2022) (1)
Phase II Trial of the Bonn Polychemotherapy Protocol with Deferred Radiotherapy in Patients with Primary Central Nervous System Lymphoma. (2006) (1)
PVAG (Prednisone, Vinblastine, Doxorubicin and Gemcitabine) In Elderly Patients with Intermediate or Advanced Stage Hodgkin Lymphoma: Final Results of a Phase II Study of the German Hodgkin Study Group (GHSG). (2010) (1)
[Recovery of paraffin blocks and central archiving : Experiences of the Kiel lymph node registry and the German study group for Hodgkin lymphoma]. (2017) (1)
Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer. (2021) (1)
Identification of Prognostic Factors in Early Unfavorable Stage Hodgkin’s Lymphoma (HL): An Individual Patient Data Meta-Analysis. (2006) (1)
Study Group Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Prognostic factors and treatment outcome in primary progressive (2013) (1)
Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan (2005) (1)
A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) (2014) (1)
Programmed cell death protein 1 ( PD 1 )-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD 1 treatment (2018) (1)
Outcome of Patients Progressing or Relapsing after Primary Treatment with Two Cycles of Chemotherapy and Radiotherapy for Early Stage (Favorable) Hodgkin’s Disease. (2005) (1)
Therapy-Related Myeloid Neoplasms (2011) (1)
Which related party transactions should be subject to ex ante review? Evidence from Germany (2019) (1)
Specific NK Cell Activation to Treat Relapsed/Refractory (r/r) Hodgkin Lymphoma (HL) Patients – Final, Updated Data on Clinical Outcome, Pharmacokinetics and Pharmacodynamics of a Phase 1 Study Investigating AFM13, a Bispecific Anti-CD30/CD16A Tandab (2014) (1)
Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: Superior results in patients younger than 60 years (2001) (1)
[Clinical use of monoclonal antibodies in malignant lymphomas]. (2001) (1)
Intensive Chemotherapy for High-Risk Patients with High-Grade Malignant Non-Hodgkin Lymphomas: A Pilot Study Using Adriamycin, Cyclophosphamide, Vincristine, Methotrexate, Etoposide, and Dexamethasone (ACOMED Protocol) (1994) (1)
Idiotype vaccination for Non‐Hodgkin lymphoma (2016) (1)
Lymphocyte-Predominant Hodgkin Lymphoma (2011) (1)
Hypomethylating agents for patients with myelodysplastic syndrome (2016) (1)
Norms, Rationality, and Communication: A Reputation Theory of Social Norms (2002) (1)
[Sarcoidosis and chronic idiopathic thrombocytopenic purpura]. (1995) (1)
Contracting Over Private Benefits of Control (2012) (1)
Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting (2016) (1)
Development of a new recombinant anti-CD30 immunotoxin (CD30L-ETA') for the treatment of Hodgkin's lymphoma (1997) (1)
Meditation for adult patients with haematological malignancies (2014) (1)
Fertility in Male Patients with Hodgkin’s Disease - Results from the German Hodgkin Lymphoma Study Group (GHSG). (2004) (1)
No Reduction of Ovarian Failure with the Use of GnRH-Analogues or Oral Contraceptives in Young Women Treated with Escalated BEACOPP for Advanced-Stage Hodgkin Lymphoma (HL). Final Results of the PROFE Trial, German Hodgkin Study Group (GHSG). (2009) (1)
Study Group (GHSG) Long-term results of a phase-II trial of the German Hodgkin Lymphoma Rituximab in relapsed lymphocyte-predominant Hodgkin Lymphoma: (2013) (1)
against malignant lymphoma The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity (2013) (1)
[New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?]. (1992) (1)
Therapiestrategien bei malignen Lymphomen (1995) (1)
The Development of Ricin A-Chain Immunotoxins for Clinical Trials in Patients with Hodgkin’s Disease (1992) (1)
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2019) (1)
Antiviral agents for prophylaxis of herpesviridae infections in patients with haematological malignancies (2011) (1)
Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients – An Analysis of GHSG HD14- and HD17-Patients (2021) (1)
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma patients (2013) (1)
[Immunotherapy strategies in lymphoma]. (1997) (1)
[Modern pharmacotherapy of Hodgkin disease]. (2004) (1)
Controversies in the management of non-Hodgkin lymphoma. (1991) (1)
S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE-PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL (2022) (1)
Role of Radiotherapy after Assessment of Residual Bulky Tumor using FDG-PET in Patients with Advanced-stage Hodgkin Lymphoma: Final Report of the GHSG HD15 Trial (2011) (1)
Ricin immunotoxins in lymphomas: Clinical application (2004) (1)
[Immunotoxin: from the idea of "magic bullets" to clinical applications]. (1990) (1)
Personalized Medicine in Hodgkin Lymphoma (2011) (1)
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. (2020) (1)
T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group (2022) (1)
Fertility in male patients with Hodgkin's disease after therapy -results from the German Hodgkin Lymphoma Study Group (GHSG). (2004) (1)
first-line chemotherapy in advanced-stage Hodgkin lymphoma progression or early relapse for patients with residual disease after Positron emission tomography has a high negative predictive value for (2013) (1)
Hodgkin Lymphoma in Adolescents Treated with Adult Protocols: An Analysis From the German Hodgkin Study Group (GHSG). (2009) (1)
Fertility in Male Hodgkin Lymphoma Patients - A Report of German Hodgkin Study Group. (2006) (1)
Hodgin’s Lymphoma in Elderly Patients: A Comprehensive Analysis of the German Hodgkin Lymphoma Study Group (GHSG). (2004) (1)
Non-Hodgkin's Lymphoma: A Review of Immunotherapeutic Approaches to Treatment. (1997) (1)
Anti-EGFR Antibody Cetuximab in Refractory or Relapsed Multiple Myeloma: Preliminary Results and Evaluation of Response Prediction in a Phase II Clinical Trial (2008) (1)
Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma (2021) (1)
[Immunotoxins. Mechanism of action and applications in malignant diseases]. (1997) (1)
Discussion Report (2006) (0)
Relative reduction of residual tumor improves outcome prediction of PET after effective chemotherapy for patients with advanced stage Hodgkin lymphoma (2012) (0)
Hematopoietic Growth Factors Reduce Side Effects of Cancer Treatment: Results of Two Comprehensive Meta-Analyses. (2004) (0)
monoclonal antibody in relapsed or refractory follicular lymphoma: First clinical use of ofatumumab, a novel fully human anti-CD20 (2013) (0)
Intravenous immunoglobulins for the treatment of infections in patients with haematological cancers (2016) (0)
Faculty Opinions recommendation of Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients w (2010) (0)
Initial radiographic response predicts favorable outcome to chemotherapy in primary CNS lymphoma (2007) (0)
Cologne (2021) (0)
High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma (2003) (0)
Consolidating Involved Field Radiotherapy Prevents Early and Local Recurrences in Early Stage Hodgkin Lymphoma (2019) (0)
[Current developments in hematology and internal medicine oncology]. (1998) (0)
Minimal residual disease following chemoimmunotherapy for patients with relapsed chronic lymphocytic leukemia (2009) (0)
Tenth Biannual Report of the Cochrane Haematological Malignancies Group—Focus on Acute Myeloid Leukemia (2009) (0)
IS there a clinical value for ricin a-chain immunotoxins in hodgkins lymphoma (2000) (0)
FDG-PET for assessment of residual tissue after completion of chemotherapy in advance stage Hodgkin lymphoma - Report on the final analysis of the PET investigation in the trial HD15 of the German Hodgkin Study Group (GHSG) (2012) (0)
Early Relapses in Primary CNS Lymphoma (PCNSL) without Intraventricular Treatment. (2007) (0)
57 INVITED PET-Response Adapted Therapy in Hodgkin Lymphoma (2011) (0)
Proceedings of the Third International Symposium on Hodgkin's Lymphoma, September 19-23, 1995, Köln, Germany (1996) (0)
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group Short title: t-AML/MDS after Hodgkin lymphoma (2017) (0)
Fourth International Symposium on Hodgkin's Disease, 28 March - 1 April 1998, Cologne, Germany (1998) (0)
Acknowledgement to Referees (2005) (0)
Abstract CT341: AFM13: an antigen specific immunotherapy for the treatment of CD30+ malignancies: Results of first-in-man study in relapsed/refractory (R/R) Hodgkin lymphoma (HL) (2014) (0)
Third International Symposium on Hodgkin's Lymphoma in Köln, Germany. (1996) (0)
Hodgkin derived cell lines L540 and L540cy grow disseminatedly in severe combined immunodeficient (SCID) mice (1993) (0)
[Role of high-dose chemotherapy in hematology and internal medicine/ oncology]. (1999) (0)
Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i) (2021) (0)
PS1317 VITAMIN D3 INHIBITS GROWTH OF HODGKIN CELL LINES AND IMPROVES SENSITIVITY TO CHEMOTHERAPY AT PHYSIOLOGICAL DOSES IN VITRO AND IN VIVO (2019) (0)
Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication (2020) (0)
[Therapy with monoclonal antibodies]. (2001) (0)
Brentuximab Vedotin (2014) (0)
Low-Dose Radiat ion Is Sufficient for the Noninvolved (2001) (0)
Comparison of the Sequential High-Dose Chemotherapy Followed by Autologous Stem Cell Support with and without Rituximab in Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma. (2004) (0)
Autologous stem cell transplantation vs chemotherapy in adult acute lymphocytic leukaemia (2011) (0)
Band 32, Heft 10, October 2009 (2009) (0)
P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma (2022) (0)
Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study (2017) (0)
Fludarabine and Fludarabine, Mitoxantrone, Dexamethasone in the Management of Low-Grade Non-Hodgkin Lymphomas (1997) (0)
Selective metalloproteinase inhibition of human CD30 shedding increases specificity of targeted immunotherapy (48.38) (2007) (0)
Acknowledgement to Reviewers (2007) (0)
123 Paclitaxel, carboplatin and G-CSF: A new approach in patients with advanced non-small cell lung cancer (NSCLC) is effective and well tolerable (1997) (0)
against malignant lymphoma activity in vivo and in vitro The human anti-CD 30 antibody 5 F 11 shows (2003) (0)
Antibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation (2016) (0)
Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy? (2006) (0)
Treatment o f P rimary P rogressive H odgkin's a nd Aggressive N on-Hodgkin's L ymphoma: I s T here a C hance for C ure? (2000) (0)
Treatment of Early Unfavorable Hodgkin Lymphoma (2020) (0)
Is there a role for immunotherapy in Hodgkin’s disease? (2009) (0)
Comparison of Patients (Pts) Characteristic and Treatment Outcomes in Lymphocyte-Predominant (LPHD) and Classical Hodgkin’s Disease (cHD): A Report from the German Hodgkin Lymphoma Study Group (GHSG). (2004) (0)
Second biannual report of the Cochrane Haematological Malignancies Group. (2005) (0)
Treatment of Early Unfavorable HL (2015) (0)
The role of Moraxella in the pathogenesis of IgD(+) nodular lymphocyte predominant Hodgkin lymphoma (2017) (0)
Screening of 19 Monoclonal Antibodies for their Potential as Ricin A-Chain Immunotoxins Against Myeloid Leukemia Cell Lines (1992) (0)
Qualitätskontrolle der Involved-Field-Radiotherapie in der HD13- und HD14-Studie : Bericht des Radiotherapiepanels der German Hodgkin Stuï»¿dy Group (GHSG). (2016) (0)
Prenylation Inhibitors as Potential Therapeutic Drugs in Hodgkin Lymphoma. (2006) (0)
Pharmacokinetics and Response to Treatment Using a Combination of Fludarabine and Alemtuzumab (FluCam) in Patients with Relapsed/Refractory CLL. (2006) (0)
The Inefficiency of Efficient Breach: An Experiment on Contract Renegotiation Under Asymmetric Information (2018) (0)
Combined local and systemic therapy improves outcomes after resection for hepatic metastases from colorectal cancer (2000) (0)
Identification of Prognostic Factors in Patients with Early Stage Unfavorable Hodgkin’s Lymphoma: An Individual Patient Data Meta-Analysis. (2005) (0)
Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin’s Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group. (2006) (0)
[Immunotherapy of hemato-oncologic diseases]. (1996) (0)
Contents Vol. 132, 2014 (2014) (0)
Prognostic Serum Cytokines in Classical Hodgkin Lymphoma—Letter (2014) (0)
Wilsede-Schule für Onkologie und Hämatologie – Wilsede School for Oncology and Hematology (1995) (0)
Quantification of Residual Tumor Cells in Monoclonal B-cell Lymphoma (2001) (0)
A Disseminated Human Neuroblastoma Model in SCID Mice (1996) (0)
Collective Intelligence (2021) (0)
Kongressbericht – Congress Report (1995) (0)
Treatment of CD30-positive diseases, such as Hodgkin's lymphoma, by administration of a combination of sheddase inhibitor and anti-CD30 immunotherapeutic agents (2008) (0)
Faculty Opinions recommendation of Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. (2009) (0)
OTT_3322_expanded use of rituximab (2009) (0)
171 : A Contribution To Solve The Problem of The Need For Consolidative Radiotherapy After Intensive Chemotherapy In Advanced Stage Hodgkin′s Lymphoma - Fourth Interim Analysis of The Multicenter Randomized Trial HD12 of The German Hodgkin Study Group (GHSG) (2006) (0)
Table C72, [KQ4: Early Changes]. (2006) (0)
Where Do Firms Incorporate Now? - National Company Law Reform and the Market for Incorporations (2010) (0)
Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients (2012) (0)
Corrigendum to "Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial": Annals of Oncology 2012; 23: 1818-1825. (2020) (0)
Biology, Staging and Treatment of Hodgkin’s Disease (1995) (0)
Hodgkin Lymphom (2022) (0)
The Updated European Hematology Association Research Roadmap (2022) (0)
P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial (2022) (0)
Mistargeting of Normal Cells in Anti-CD30 Immunotherapy of Lymphoma Cells Is Blocked by Selective Metalloproteinase Inhibitor. (2006) (0)
Impact of age and socio-economic inequalities in cancer survival of patients with Hodgkin's lymphoma diagnosed in England and Wales (2006) (0)
Targeting CD30 in Patients with Hodgkin Lymphoma (2015) (0)
First‐line double high‐dose chemotherapy and autologous stem cell transplantation versus single high‐dose chemotherapy and autologous stem cell transplantation in multiple myeloma (2008) (0)
Chapter 3. Shareholder Conflicts in Closed Corporations (2013) (0)
Concordance in interpretation of FDG PET after chemotherapy in advanced stage Hodgkin lymphoma (2015) (0)
Immunotoxins against the vasculature of human Hodgkin’s lymphoma in SCID mice (2007) (0)
[Patient participation in the Cochrane Collaboration--barriers, experience, and concepts in Germany]. (2005) (0)
Third biannual report of the Cochrane Haematological Malignancies Group. (2005) (0)
Treatment of Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Subgroup Analysis of the Randomized German Hodgkin Study Group HD16 Study (2021) (0)
Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials. (2012) (0)
Neoplastic Diseases of The Blood P.H. Wiernik, J.M. Goldman, J. Dutcher and R.A. Kyle (Eds.) Springer Science+Business Media, New York, 5th Edn 2013, XIX, 1431 pages. 224 illustration, 143 in color. ISBN 978-1-4614-3764-2 (2013) (0)
Tentative Diagnosis of Lung Cancer in a Patient with Lipoid Pneumonia (1998) (0)
Quality Assurance of Involved Field Radiation Therapy Within the HD13 and HD14 Trial (early stages) of the German Hodgkin Study Group (2015) (0)
HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL SUPPORT IN FIRST LINE TREATMENT OF AGGRESSIVE NON HODGKIN LYMPHOMA: RESULTS OF AN INDIVIDUAL PATIENT DATA META-ANALYSIS (2009) (0)
Treatment of Centroblastic-Centrocytic and Centrocytic Lymphomas at Advanced Stages — Results of the German Low-Grade Lymphoma Study Group (1998) (0)
The role of granulopoiesis-stimulating factors in the treatment of malignant lymphoma (2001) (0)
[Monoclonal antibodies in therapy of malignant lymphomas]. (1998) (0)
Polychemotherapy in patients with primary CNS lymphoma. (2004) (0)
Evolution of adjuvant chemotherapy for breast cancer (2015) (0)
Allogeneic Stem Cell Transplantation for Relapsed Hodgkin’s Disease - a Single Centre Experience (2008) (0)
Long-Term Disease Control in Patients with Primary Central Nervous System Lymphoma (2008) (0)
Elderly Patients with Early-Unfavorable Stage Hodgkin’s Disease (HD) Have a Poorer Outcome When Treated with Combined Modality Treatment and Extended Field Radiotherapy (EF): A Retrospective Analysis of the German Hodgkin Study Group. (2004) (0)
Brief an die Herausgeber · Letter to the Editors (2009) (0)
T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies (2022) (0)
[Monoclonal antibodies: development and clinical prospects]. (2001) (0)
Impact of bone marrow involvement on early positron emission tomography response and progression‐free survival in the HD18 trial for patients with advanced‐stage Hodgkin lymphoma (2021) (0)
Chapter 6. Formation, Management and Transfer of Shares (2013) (0)
P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma (2022) (0)
GRANULOCYTE‐COLONY STIMULATING FACTOR (G‐CSF) IN PATIENTS UNDERGOING SURGERY FOR ESOPHAGEAL CANCER REDUCES INFECTIOUS COMPLICATIONS IN THE PERIOPERATIVE PERIOD: 306 (1997) (0)
Antitumor Effects of Six Ricin A-Chain Immunotoxins of Potential Use in the Treatment of Hodgkin’S Disease (1990) (0)
A phase I clinical trial of an anti-CD25-deglycosylated ricin a-chain immunotoxin (RFT5-SMPT-DGA) in patients with Hodgkin’s lymphoma restistent to conventional therapy (2007) (0)
Chapter 7. Regulatory Features of a European Closed Corporation (2013) (0)
Hodgkin lymphoma 282 NODULAR SCLEROSIS-TYPE CLASSICAL HODGKIN LYMPHOMA IN THE ELDERLY: POOR PROGNOSIS AND HETEROGENEOUS NATURE NODE FOR NON-BULKY STAGE I-II PRELIMINARY RESULTS THE STANFORD G5 STUDY (2011) (0)
Hodgkin Study Group (GHSG) lymphocyte-predominant Hodgkin lymphoma: a report from the German The prognostic impact of variant histology in nodular (2013) (0)
Primary C entral N ervous S ystem L ymphoma: R esults o f a P ilot and P hase I I S tudy o f S ystemic a nd I ntraventricular Chemotherapy W ith D eferred R adiotherapy (2003) (0)
Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group (2022) (0)
Recommendations from the society for diagnosis and therapy of haematological and oncological diseases Guideline Hodgkin ’ s Lymphoma (2016) (0)
Abstract of the international symposium acute leukemias V experimental approaches and management of refractory disesses (2005) (0)
antibodies in combination with bivalent CD28 antibodies leukemia by autologous T cells activated with CD3 x CD19 bispecific Lysis of malignant B cells from patients with B-chronic lymphocytic (2011) (0)
P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16 (2022) (0)
Establishing a New Quality Assurance Program of “Modern” Radiation Therapy Within the German Hodgkin Study Group (2015) (0)
Why Manager Liability Fails at Controlling Systemic Risk (2014) (0)
Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation (2012) (0)
The corporate group as an organizational form – Separating control from value appropriation (2016) (0)
TRENDS AND SOCIO-ECONOMIC INEQUALITIES IN CANCER SURVIVAL OF PATIENTS WITH HODGKIN’S DISEASE DIAG- NOSED IN ENGLAND AND WALES BETWEEN 1986 AND 1999 (2005) (0)
Antibiotics plus colony stimulating factors (CSFs) versus CSFs alone and antibiotics plus CSFs versus no prophylaxis for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation (2009) (0)
FromTreatmentFailure forPatientsWithHodgkin Lymphoma (2013) (0)
Clinical Investigation of the Monoclonal Anti-CD20 Antibody Rituximab (IDEC-C2B8) in Patients with B Cell Lymphoma (1999) (0)
Acknowledgement to Reviewers (2013) (0)
PET-Guided Treatment in Patients with Early-Stage Favorable Hodgkin Lymphoma: Follow-up Analysis of the HD16 Trial By the German Hodgkin Study Group (2021) (0)
Quality of Life in a 2-Year Follow-up: Signs of PNP Predicting Cognitive Functioning in Survivors Treated in the HD10–12 Trials of the German Hodgkin Study Group (GHSG). (2008) (0)
First‐line stem cell transplantation from related donors compared to immunosuppressive treatment for acquired severe aplastic anaemia (2007) (0)
Subject Index Vol. 23, 2000 (2000) (0)
Rituximab Added to an Intensified Salvage Chemotherapy Program Followed by Autologous Stem Cell Transplantation Improve in Relapsed and Refractory Aggressive Non-Hodgkin-Lymphoma. (2005) (0)
Role of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial (2022) (0)
Abstract 4572: The CD30/CD16A RECRUIT TandAb AFM13 activates patient NK cells resulting in specific tumor cell killing. (2013) (0)
What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma? (2015) (0)
Chapter 5. Creditor Protection in the Closed Corporation (2013) (0)
P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group (2022) (0)
P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma (2022) (0)
Migration and interleukin-8 release of granulocytes by soluble and nanovesicle-associated CD30 from hodgkin lymphoma cells (2009) (0)
The German Hodgkin Study Group (GHSG)--15 Years of Experience in Treating Early and Intermediate Stages of Hodgin??s Disease: 10:45 AM (20) (2002) (0)
Florian Möslein, Dispositives Recht (Mohr Siebeck 2011) XX and 640 pages (2013) (0)
malignancies: the German Hodgkin Study Group experience Brentuximab vedotin for relapsed or refractory CD30+ hematologic (2013) (0)
HemaSphere: A New Rising Star in the Field of Hematology Journals (2018) (0)
Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis (2021) (0)
Secondary Myeloid Leukemia and MDS in Patients Treated for Hodgkin Lymphoma - Experience of the German Hodgkin Lymphoma Study Group (GHSG) (2009) (0)
High-dose therapy with autologous stem cell transplantation for patients with chronic lymphocytic leukaemia (2011) (0)
Reporting of Randomised Controlled Trials in Hodgkin’s Lymphoma from 1966 to 2002. A Pre- and after CONSORT Evaluation. (2005) (0)
Low dose cytarabine monotherapy for acute myeloid leukaemia (2016) (0)
Collective Intelligence: Crowd Wisdom versus Herding (2020) (0)
Axillary swelling and a reduced general condition in a middle-aged man (2004) (0)
Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials. (2020) (0)
PS1240 EVEROLIMUS WITH DHAP (DEXAMETHASONE, HIGH-DOSE ARAC, CISPLATINUM) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A RANDOMIZED, PLACEBO-CONTROLLED PHASE I/II TRIAL (HD-R3I) (2019) (0)
Chapter 4. The Board of Directors (2013) (0)
Paclitaxel, Carboplatin, and G-CSF in Advanced Non-Small-Cell Lung Cancer: A Phase I/II Study (1998) (0)
B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma. (2023) (0)
Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation (2018) (0)
[Hematology and internal medicine oncology]. (1999) (0)
HLA‐B‐Associated Transcript 3 (BAT3), a ligand for Nkp30 is secreted from cells as Exosomes and enhances the activity of Natural Killer cells (2008) (0)
Current Aspects in the treatment of Hodgkin's Lymphoma Current status and research developments (2007) (0)
A Bispecific Protein Targeting the NKG2D Receptor on Natural Killer Cells: In Vitro and In Vivo activity of ULBP2-CEA (2010) (0)
Contents, Vol. 16, 1993 (1983) (0)
Chemotherapy of human lymphoma cell lines after heterotransplantation in nude mice (1986) (0)
High‐dose chemotherapy with autologous stem cell support for first‐line treatment of aggressive non‐Hodgkin lymphoma: a systematic review and meta‐analysis based on individual patient data (2016) (0)
Low dose cytarabine monotherapy for myelodysplastic syndromes (2016) (0)
[Controversies in therapy of malignant lymphomas]. (1994) (0)
The Superior Prognosis of Female Patients with Hodgkin’s Lymphoma Is Related to More Treatment-Induced Leucopenia and Warrants a More Individualized Therapy. (2004) (0)
40 Secondary leukaemia and myolodysplastic syndromes in patients successfully treated for Hodkgin lymphoma: a report from the German Hodgkin Study Group (2009) (0)
8. Rodel C, Grabenbauer Gg, Kuhn R Et Al.. Combined-modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-term Results. Comparing Long-term Toxicity and Efficacy of Combined Modality Treatment including Extended-or Involved-field Radiotherapy in Early-stage Hodgkin's L (0)
Market Standards in Financial Contracting: The Euro’s Effect on European Debt Securities (2015) (0)
Role of CD30/CD30L Mediated Signaling in the Cross‐talk of Natural Killer Cells and Dendritic Cells (2008) (0)
Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma (2018) (0)
Ifosfamide in the Treatment of Relapsed Lymphoma (1998) (0)
Hodgkin ' s Lymphoma in the Elderly : A Different Disease in Patients Over 60 Review (2017) (0)
Chapter 1. Introduction and Objectives (2013) (0)
Perioperative immunotherapy with recombinant granulocyte-colony stimulating factor in patients undergoing surgery for esophageal cancer (1996) (0)
Selection of human anti-CD22 scFvs from an acute lymphocytic leukemia related scFv library with ribosome display. (2006) (0)
HSR19-107: Nivolumab for Newly Diagnosed Classical Hodgkin Lymphoma: Patient-Reported Outcomes From CheckMate 205 Cohort D (2019) (0)
CLINICAL OUTCOMES OF RELAPSED HODGKIN LYMPHOMA PATIENTS AFTER CONTEMPORARY FIRST‐LINE TREATMENT: RESULTS FROM THE GERMAN HODGKIN STUDY GROUP (2021) (0)
Relapse of Central Nervous System Lymphoma after systemic Lymphoma (SCNSL): Clinical Features and Outcome as compared to Primary CNS Lymphoma (PCNSL) Patients (2008) (0)
S819 PET AFTER 2 CYCLES OF ABVD IN PATIENTS WITH EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA TREATED WITHIN THE PHASE 3 GHSG HD16 STUDY (2019) (0)
Soluble CD30 receptor from Hodgkin cells stimulates granulocytes to release angiogenic interleukin‐8 (2008) (0)
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2017) (0)
Hodgkin-Lymphom (2014) (0)
Hodgkin Lymphoma-ReadingSample (2014) (0)
5. Interdisziplinärer Kongress „Quality of Cancer Care“ (QoCC 2021) (2021) (0)
HDCT, IMMUNTHERAPIE, NEUE ZYTOSTATIKA (1996) (0)
GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY (2017) (0)
Preliminary results of a Phase II study: combined systemic polychemotherapy and intrathecal treatment with liposomal cytarabine in patients with primary CNS lymphoma ≥60 years (2009) (0)
Preclinical and clinical data for tbo-filgrastim: A short-acting filgrastim. (2013) (0)
Treatment options in nodular lymphocyte-predominant Hodgkin lymphoma (2013) (0)
Faculty Opinions recommendation of High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. (2010) (0)
Role and Extent of Surgery in Multimodality Treatment (1999) (0)
New Agents for Patients with Hodgkin Lymphoma (2011) (0)
A Comparison of Outcome and Second Malignancies in Adolescents and Adult Patients with Hodgkin’s Lymphoma (HL). Results from the German Hodgkin Study Group. (2005) (0)
[Immune dysregulation and malignant lymphoma]. (1995) (0)
Quality Control of Involved Field (IF)-radiotherapy for Patients with Early-stage Hodgkin Lymphoma Based on a Central Prospective Review: Comparison of the Results between Two Study Generations of the German Hodgkin Study Group (GHSG) (2010) (0)
Radioimmunotherapy Utilizing the Humanized Anti-CD25 Mab Daclizumab Is Highly Effective in Mice Bearing Human Hodgkin’s Lymphoma Xenografts. (2004) (0)
Table C47, [KQ2: Studies Not Included for Hematologic Response]. (2006) (0)
Secondary M yeloid L eukemia a nd M yelodysplastic S yndromes in P atients T reated f or H odgkin's D isease: A R eport F rom t he German H odgkin's L ymphoma S tudy G roup (2003) (0)
pBM1.1, a new pET-based vector for high efficiency expression of ETA′ fusion toxins (1997) (0)
Reply to H.J.A. Adams et al. (2020) (0)
Hypomethylating agents for adult patients with acute myeloid leukaemia (2016) (0)
Panel Discussions and Presentations (2005) (0)
Lymphoma: Hodgkin's lymphoma (2007) (0)
Engaging the NKG2D Receptor with a Novel Bispecific Protein (ULBP2-antiCD138) Activates NK Cells and Has Potent Antitumor Activity Against Human Multiple Myeloma. (2005) (0)
Session 15: Hodgkin lymphoma 159 GENETIC POLYMORPHISMS INFLUENCE THE RISK OF HODGKIN’S LYMPHOMA (2011) (0)
Purine analogues plus cyclophosphamide versus purine analogues alone for first‐line therapy of patients with chronic lymphocytic leukaemia (2016) (0)
Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group (2015) (0)
Leucopenia during Treatment Is a Good Prognostic Risk Factor for Patients Undergoing Chemotherapy for Hodgkin’s Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG). (2005) (0)
HLA-B-Associated Transcript 3 (BAT3) is an activating ligand for NKp30 and released from dendritic cells (48.2) (2007) (0)
1568. Implementation of a Standard Diet Regimen for Neutropenic High-Risk Cancer Patients: Effects on Incidence of Infections, Foodborne Diseases, and Outcome (2018) (0)
P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma (2022) (0)
P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma (2022) (0)
Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude (2017) (0)
Table 30, [Features of Studies Reporting Tumor Response or Duration-Related Outcomes]. (2006) (0)
Seasonal Differences in Incidence and Survival of Hodgkin Lymphoma Depend on Geographic Location of Diagnosis (2016) (0)
“Quality of Life (QoL) in the Randomised HD10-12 Trials of the German Hodgkin Study Group (GHSG): Sexual Functions (SX) in Hodgkin Lymphoma (HL) Patients Decrease by Disease Stage and Improve After Therapy Depending On Stage and Treatment Modality.”. (2009) (0)
(RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's Lymphoma A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (1997) (0)
Rituximab for Patients with Chronic Lymphocytic Leukemia: A Systematic Review (2010) (0)
Human immune response to ricin A-chain: identification of T-cell and B-cell epitopes. (2004) (0)
Recommendations from the society for diagnosis and therapy of haematological and oncological diseases Hodgkin ’ s Lymphoma (2019) (0)
Proceedings of the 13th biennial South African Lymphoma Study Group Meeting--Cape Town October 2008. (2010) (0)
Systematic Review and Individual Patient Data Meta-Analysis Of Treatment-Related Risk Of Secondary Malignant Neoplasms After Hodgkin Lymphoma (2013) (0)
Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group (2015) (0)
Treatment of early favorable and early unfavorable hodgkin lymphoma – combined modality therapy ? (2016) (0)
Clinical safety of tbo-filgrastim in chemotherapy-induced neutropenia: Integrated analysis of the phase III studies. (2013) (0)
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO) (2022) (0)
Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial (2022) (0)
PS1243 JAK-INHIBITION WITH RUXOLITINIB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A PHASE II, OPEN LABEL, MULTICENTER CLINICAL TRIAL (JERICHO) (2019) (0)
Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma. (2023) (0)
Prolonged Remission in a Patient with Relapsed Follicular Lymphoma after a Single Course of Rituximab (2006) (0)
The Fifth Year of HemaSphere (2021) (0)
Biannual report of the Cochrane Haematological Malignancies Group. (2004) (0)
Study Group lymphocyte-predominant Hodgkin lymphoma : a report from the German Phase 2 study of rituximab in newly diagnosed stage IA nodular (2011) (0)
Positron emission tomography (PET)‐adapted therapy for Hodgkin lymphoma patients (2013) (0)
P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial (2022) (0)
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2019) (0)
[Pathogenesis and therapy of Hodgkin lymphoma]. (1998) (0)
Chapter 2. Analytical Framework (2013) (0)
Randomized , Double-Blind , Placebo-Controlled , Phase I 11 Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as Adjunct to Induction Treatment of High-Grade Malignant Non-Hodgkin ' s Lymphomas (2003) (0)
PET-based response assessment in Hodgkin lymphoma patients undergoing PD-1 blockade: data of the German Hodgkin Study Group NIVAHL trial for early unfavorable stages (2021) (0)

This paper list is powered by the following services:

Other Resources About Andreas Engert

www.jura.fu-berlin.de

What Schools Are Affiliated With Andreas Engert?

Andreas Engert is affiliated with the following schools:

University of Bologna
University of Innsbruck
University of Mannheim
Humboldt University of Berlin
University of Erlangen–Nuremberg
University of Cologne
University of Verona
Free University of Berlin
Humanitas University